2020 was the seminal year when several biotechnology firms from the psychedelic space IPOed as investments into curing mental illness continued to gain traction among investors.
Psychedelic drugs such asPsilocybin, LSD and Ketamine have long shown great potential in treating severe psychiatric conditions like depression,addiction, post-traumatic stress disorders and other conditions.
Sign- up to receive the latest inputs and newsletters on the financial markets
© Copyright 2017 Take Stock Research. All Rights Reserved.